[go: up one dir, main page]

MX2018009500A - Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas. - Google Patents

Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.

Info

Publication number
MX2018009500A
MX2018009500A MX2018009500A MX2018009500A MX2018009500A MX 2018009500 A MX2018009500 A MX 2018009500A MX 2018009500 A MX2018009500 A MX 2018009500A MX 2018009500 A MX2018009500 A MX 2018009500A MX 2018009500 A MX2018009500 A MX 2018009500A
Authority
MX
Mexico
Prior art keywords
crystalline forms
maleate salt
salt
preparation methods
tlr7 agonist
Prior art date
Application number
MX2018009500A
Other languages
English (en)
Other versions
MX374295B (es
Inventor
Ding Zhaozhong
Yang Ling
Wang Zheng
Sun Fei
Hu Yinghu
Zhou Yilong
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2018009500A publication Critical patent/MX2018009500A/es
Publication of MX374295B publication Critical patent/MX374295B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a una sal de maleato del compuesto representado por formula I, un metodo para prepara la sal, una composicion farmaceutica que contiene la sal y el uso de la sal; la presente invencion ademas se refiere a las formas cristalinas C, 5 D y E de la sal de maleato del compuesto representado por formula I; a los metodos para preparar las formas cristalinas, composiciones cristalinas y composiciones farmaceuticas que contienen las formas cristalinas, y a su uso.
MX2018009500A 2016-02-05 2017-02-04 Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas. MX374295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082030.0A CN107043380A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
PCT/CN2017/072890 WO2017133683A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2018009500A true MX2018009500A (es) 2018-12-11
MX374295B MX374295B (es) 2025-03-06

Family

ID=59500111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009500A MX374295B (es) 2016-02-05 2017-02-04 Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas.

Country Status (23)

Country Link
US (2) US10780091B2 (es)
EP (1) EP3412671B1 (es)
JP (1) JP6898336B2 (es)
KR (1) KR102393279B1 (es)
CN (2) CN107043380A (es)
AR (1) AR107547A1 (es)
AU (1) AU2017215800B2 (es)
CA (1) CA3013682C (es)
CL (1) CL2018002089A1 (es)
DK (1) DK3412671T3 (es)
EA (1) EA038794B1 (es)
ES (1) ES2834303T3 (es)
HU (1) HUE052211T2 (es)
IL (1) IL260965B (es)
MX (1) MX374295B (es)
MY (1) MY196762A (es)
NZ (1) NZ745231A (es)
PH (1) PH12018501644B1 (es)
SG (1) SG11201806682TA (es)
TW (1) TWI778951B (es)
UA (1) UA123781C2 (es)
WO (1) WO2017133683A1 (es)
ZA (1) ZA201805185B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
JP7385602B2 (ja) 2018-05-25 2023-11-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 肺癌を治療するためのtlr7アゴニストおよびその医薬の組み合わせ
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
DE69731823T2 (de) 1996-07-03 2005-12-15 Sumitomo Pharmaceuticals Co., Ltd. Neue purinderivate
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
EP1931352B1 (en) 2005-08-22 2016-04-13 The Regents of The University of California Tlr agonists
BRPI0813952A2 (pt) 2007-06-29 2017-05-09 Gilead Sciences Inc derivados de purina e seu emprego como moduladores e receptor 7 semelhante ao dobre de sino
EP2188280B1 (en) 2007-08-03 2011-03-09 Pfizer Limited Imidazopyridinones
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
ES2670513T3 (es) * 2012-10-10 2018-05-30 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades
KR20150085080A (ko) * 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
AU2013348216B2 (en) * 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
BR112015011400A8 (pt) 2012-11-20 2019-10-01 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
US9902730B2 (en) 2014-05-01 2018-02-27 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
JP6541689B2 (ja) * 2014-05-01 2019-07-10 ノバルティス アーゲー Toll様受容体7アゴニストとしての化合物および組成物
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EP3190113B1 (en) 2014-08-15 2021-05-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as tlr7 agonist
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
AU2016349662A1 (en) 2015-11-05 2018-05-17 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
EP3381918B1 (en) 2015-11-05 2020-09-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
US20200368241A1 (en) 2020-11-26
JP6898336B2 (ja) 2021-07-07
AR107547A1 (es) 2018-05-09
EP3412671B1 (en) 2020-09-16
EP3412671A4 (en) 2019-07-24
WO2017133683A1 (zh) 2017-08-10
IL260965B (en) 2022-02-01
HUE052211T2 (hu) 2021-04-28
TWI778951B (zh) 2022-10-01
PH12018501644B1 (en) 2022-09-07
AU2017215800A1 (en) 2018-08-30
SG11201806682TA (en) 2018-09-27
MX374295B (es) 2025-03-06
KR20180104116A (ko) 2018-09-19
UA123781C2 (uk) 2021-06-02
CN107043380A (zh) 2017-08-15
PH12018501644A1 (en) 2019-06-03
CL2018002089A1 (es) 2018-12-07
AU2017215800B2 (en) 2020-08-20
CA3013682A1 (en) 2017-08-10
NZ745231A (en) 2022-07-29
EA201891770A1 (ru) 2019-01-31
JP2019505532A (ja) 2019-02-28
US20190070179A1 (en) 2019-03-07
US10780091B2 (en) 2020-09-22
CN108602830A (zh) 2018-09-28
ES2834303T3 (es) 2021-06-17
EP3412671A1 (en) 2018-12-12
HK1259175A1 (zh) 2019-11-29
ZA201805185B (en) 2024-08-28
EA038794B1 (ru) 2021-10-20
DK3412671T3 (da) 2020-11-09
CA3013682C (en) 2022-06-21
TW201728588A (zh) 2017-08-16
KR102393279B1 (ko) 2022-05-02
CN108602830B (zh) 2020-07-28
MY196762A (en) 2023-05-03
BR112018015881A2 (pt) 2018-12-26

Similar Documents

Publication Publication Date Title
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
ECSP14004812A (es) Triazolopiridinas sustituidas
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2017001675A1 (es) Derivados de quinazolina utilizados para tratar el vih
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CU20170009A7 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CO2020007018A2 (es) Proceso para preparar tapinarof
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
MX385720B (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen.
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
ECSP13013011A (es) Triazolopiridinas
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
UY36651A (es) Compuestos antiestrogénicos
CR20160016A (es) Pirazolpiridinas sustituidas
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CR20190379A (es) Moduladores del receptor de estrógeno
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende

Legal Events

Date Code Title Description
FG Grant or registration